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E-mail address: adrianw@uga.eduMany of the anthelmintic drugs in use today act on the nematode nervous system. Ion channel targets
have some obvious advantages. They tend to act quickly, which means that they will clear many infec-
tions rapidly. They produce very obvious effects on the worms, typically paralyzing them, and these
effects are suitable for use in rapid and high-throughput assays. Many of the ion channels and enzymes
targeted can also be incorporated into such assays. The macrocyclic lactones bind to an allosteric site on
glutamate-gated chloride channels, either directly activating the channel or enhancing the effect of the
normal agonist, glutamate. Many old and new anthelmintics, including tribendimidine and the amino-
acetonitrile derivatives, act as agonists at nicotinic acetylcholine receptors; derquantel is an antagonist
at these receptors. Nematodes express many different types of nicotinic receptor and this diversity means
that they are likely to remain important targets for the foreseeable future. Emodepside may have multi-
ple effects, affecting both a potassium channel and a pre-synaptic G protein-coupled receptor; although
few other current drugs act at such targets, this example indicates that they may be more important in
the future. The nematode nervous system contains many other ion channels and receptors that have not
so far been exploited in worm control but which should be explored in the development of effective new
compounds.
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Parasitic nematodes remain serious pathogens of humans
(Brooker et al., 2010), their animals (both domestic and livestock)
(McKellar and Jackson, 2004) and plants (Sasser, 1980; Davis and
Mitchum, 2005). They infect a very large proportion of the people
on the planet, with serious and frequently underestimated effects
on their physical, intellectual and economic development, and
‘steal’ an enormous amount of our food by parasitizing the plants
and animals we use to feed ourselves. For these reasons, their con-
trol, and possible eventual elimination, remains a major priority in
international public health and agriculture. In the continued ab-
sence of effective vaccines and major improvements in human san-
itation, chemotherapy and chemoprophylaxis are the only viable
options for large-scale control and elimination efforts.
Many of the drugs currently used for these purposes target the
nematode nervous system, and in many ways this is not surprising.
The nervous system makes up about 30% of all of the cells in nem-
atodes, based on work with Caenorhabditis elegans (White et al.,
1986), and many worms need to move continuously to maintain
their position in the host. In the case of parasites of the gastro-
intestinal tract, paralysis will result in their rapid removal. In
addition, the presence or absence of observable locomotion is fre-
quently used as a quick and easy method of telling whether nem-
atodes are alive or dead – many species move vigorously and
continuously – and so makes a useful screen for anthelmintic activ-
ity. This has been further developed into assays such as the larval
migration inhibition assay (Wagland et al., 1992; Kotze et al., 2006)
and others which rely on inhibition of locomotion to measure sus-
ceptibility and resistance to anthelmintic compounds (Kotze et al.,
2004); these may have the potential to be at least partially auto-
mated (Smout et al., 2010; Carr et al., 2011). However, nematodes
do more than just move; they also feed, mate, and detect and re-
spond to environmental cues. All of their behaviors are, of course,
controlled by the nervous system and may have potential as
anthelmintic targets. The nervous system of nematodes is anatom-
ically simple, generally containing about 300 neurons (White et al.,
1986), and is well conserved between species (Goldschmidt, 1909),
but is neurochemically extremely complex, using many transmit-
ter and receptor combinations that are not present in mammals.Table 1
Anthelmintics in current use.
Drug Target Statu
Benzimidazoles
(albendazole,
mebendazole)
b-Tubulin Wid
Glob
Filar
Macrocyclic lactones
(ivermectin, moxidectin)
Glutamate-gated chloride channels IVM
Cont
med
Piperazine derivatives
(diethylcarbamazine)
Piperazine is an agonist at GABA receptors,
DEC has a different mode of action, not fully
understood
DEC
Imidazothiazoles
(levamisole)
Nicotinic acetylcholine receptors Wid
Tetrahydropyrimidine
derivatives (pyrantel,
oxantel, morantel)
Nicotinic acetylcholine receptors Used
anim
Trich
Amino-acetonitrile
derivatives (monepental)
Choline receptors Rece
Tribendimidine Nicotinic acetylcholine receptors Appr
Spiroindoles (derquantel) Nicotinic acetylcholine receptors Used
Cyclic depsipeptides
(emodepside)
SLO-1 potassium channels? Latrophilin
receptors?
Used
Doxycycline Wolbachia endosymbiontsThis complexity opens a rich seam of possibilities as anthelmintic
targets, but also makes elucidating their exact mechanisms of ac-
tion a real challenge. The situation is further complicated because
the neurochemistry, unlike the anatomy, also varies considerably
between nematode species, especially in terms of the size and
complexity of some of the receptor and ion channel families (Wil-
liamson et al., 2007; Wolstenholme et al., 2011).
In this review, I will discuss the neuroactive drugs currently
used to treat and prevent parasitic nematode infections, and our
current understanding of how they work. There have been some
major advances in this area in the last few years, both in the intro-
duction of new compounds (Kaminsky et al., 2008a; Little et al.,
2011) and new information about the way that some of the exist-
ing ones, especially the macrocyclic lactones (MLs), work (Lynagh
and Lynch, 2010b; Hibbs and Gouaux, 2011). These advances have
not only increased our knowledge of the mechanisms of action of
these compounds, but may also suggest novel ways in which they
can be used to reduce the problems caused by drug resistance
(Wolstenholme et al., 2004; Kaplan and Nielsen, 2010;
Osei-Atweneboana et al., 2011; Sutherland and Leathwick, 2011;
Vercruysse et al., 2011). I will also brieﬂy discuss how other parts
of the nematode nervous system might make attractive drug tar-
gets, and how they may be affected by our current compounds. I
will concentrate on human and animal parasites, as those are the
ones targeted by the drugs under discussion; however, several as-
pects may also be applicable to the plant parasitic species.
2. Drugs currently available
A variety of compounds is currently used in the treatment and
prevention of parasitic nematode infections. The most important
are listed in Table 1, which also demonstrates how many of these
drugs speciﬁcally target molecules found in neurons and muscles.
In fact all of them, except for the benzimidazoles, diethylcarbami-
zine (DEC) and doxycyline, which affect theWolbachia endosymbi-
ont of ﬁlarial species, act at the ion channels found on nematode
nerves and muscles. Many of these targets are widely conserved
in animals, including mammals, so at ﬁrst glance the selective tox-
icity of the drugs for nematodes, and, in some cases, other inverte-
brates might be surprising, and by some criteria molecules such ass References
ely used in human and animal medicine. Part of
al Program for the Elimination of Lymphatic
iasis (GPELF)
Kohler (2001) and
Ottesen et al. (2008)
is a mainstay of African Program for Onchocerciasis
rol, and is used in GPELF. Widely used in animal
icine
Wolstenholme and
Rogers (2005) and
Amazigo (2008)
is widely used in humans, as part of GPELF Martin (1985) and
Bockarie and Deb (2010)
ely used in animal medicine Keiser and Utzinger
(2008) and Sattelle
(2009)
to treat some human infections. Widely used in
al medicine. Oxantel is especially effective against
uris spp.
Kopp et al. (2008)
ntly introduced for use in sheep Kaminsky et al. (2008a)
and Sager et al. (2009)
oved in China for human use Steinmann et al. (2008)
and Hu et al. (2009)
in combination with abamectin in sheep (NZ) Robertson et al. (2002)
and Little et al. (2011)
in combination with praziquantel in cats and dogs Welz et al. (2011)
Hoerauf et al. (2003)
Table 2
Ion channel and receptor genes encoding anthelmintic targets in C. elegans and parasitic nematodes. Nematodes contain a plethora of genes encoding receptors and ion channels
and it is beyond the scope of this article to provide a full comparison between the species. Shown here are the C. elegans genes that have been shown to encode components of
anthelmintic drug targets, along with the equivalent target genes in H. contortus and, where available, selected other parasitic species. Members of the gene families that have not
been shown to encode drug targets (e.g. the predicted GluCl gene glc-4) have been excluded. Older gene names, especially for H. contortus, used in the literature are shown in
brackets.
Drug class Target C. elegans genes H. contortus
genes
Other parasites
Macrocyclic lactones GluCl glc-1 Hco-glc-2b
(HG4)
avr-14 is present in all species examined. glc-2 is present in
clades 3, 4 and 5. glc-3 is present in clades 4 and 5
glc-2 (when co-
expressed with glc-
1)
Hco-glc-3b
glc-3 Hco-avr-14b
(HG3, GluCla3B)
avr-14ba (gbr-2b) Hco-glc-5
(GluCla, HG5)
avr-15 Hco-glc-6b
Piperazine GABA
receptors
unc-49 Hco-unc-49 unc-49 is widely conserved in nematodes
Imidazothiazoles, tetrahydropyrimidine,
tribendimidine, spiroindoles
nAChR lev-1 Hco-acr-8 acr-8, unc-29, unc-38 and unc-63 are widely conserved
lev-8 Hco-lev-1c
unc-29 Hco-unc-29d
unc-38 Hco-unc-38
unc-63 Hco-unc-63
AADs Choline
receptors
acr-23 Hco-mptl-1e acr-23/mptl-1is absent from clade 1, 3 and 4 parasites
deg-3 Hco-deg-3
des-2 Hco-deg-2
Cyclic depsipeptides Potassium
channels
slo-1 Hco-slo-1 Widely conserved
Cyclic depsipeptides Latrophilin
receptors
lat-1 Hco-lat-1 (Hc-
110R)
Widely conserved
a The avr-14 gene is alternatively spliced to give two subunits, AVR-14A and AVR-14B. To date, only AVR-14B has been shown to form a ML target.
b These genes have not been formally shown to encode components of an ML-sensitive receptor.
c Hco-lev-1 encodes a nAChR subunit that lacks an N-terminal signal peptide and has not been shown to contribute to a functional channel or drug target.
d Hco-unc-29 has undergone at least two rounds of gene duplication, resulting in four genes, Hco-unc-29.1 to Hco-unc-29.4.
e Hco-mptl-1 has not been formally shown to encode part of a monepantel-sensitive receptor.
4 A.J. Wolstenholme / International Journal for Parasitology: Drugs and Drug Resistance 1 (2011) 2–13nicotinic acetylcholine receptors and potassium channels would
not be considered attractive for developing drugs speciﬁc for hel-
minths. However, these receptors and ion channels possess a com-
plex pharmacology, with multiple allosteric and regulatory sites
(Kaczorowski et al., 1996; Wu et al., 2006; Thompson et al.,
2010), and this has led to a large pharmacopeia of useful com-
pounds, often with very selective actions. Many of the genes that
code for these proteins are nematode-speciﬁc and well-conserved
within the phylum (Table 2), which goes some way to explaining
the broad spectrum of many of the drugs that affect them. It would
be no surprise if these ‘old’ targets continue to supply us with
important new drugs for several years to come.3. Cys-loop ligand-gated ion channels as anthelmintic targets
One of the reasons that this family of receptors, which includes
the glutamate-gated chloride channels (GluCl) and the nicotinic
acetylcholine receptors (nAChR), has been so useful to those who
wish to kill parasites is that it is large and diverse. Though the fam-
ily is conserved between nematode species, and even between
nematodes and mammals, its size and composition varies greatly,
which has resulted in the identiﬁcation of highly speciﬁc and po-
tent drugs. All of the members of this family possess the same basic
architecture, with ﬁve similar subunits surrounding a central pore;
the channels open on binding of a speciﬁc ligand to the extracellu-
lar part of the receptor, allowing ions to pass down electro-chem-
ical gradients into or out of the cell (Thompson et al., 2010). The
ions that are allowed to pass through can be cations (Na+, K+ and
Ca++) or anions (Cl) and the ligands that gate the channels vary
considerably, though many are, or are derived from, amino-acids
(e.g. glutamate and GABA) and biogenic amines (e.g. 5-HT (seroto-
nin), dopamine and tyramine).A very important family of receptors in all nervous systems, the
ionotropic glutamate receptors (iGluR), is not the target for any
current anthelmintic drugs, despite the vital roles of this family
of receptors in the nematode central nervous system (Aronoff
et al., 2004; Kano et al., 2008). These receptors have quite a differ-
ent architecture to the GluCl and nAChR (Mayer, 2011); perhaps
this restricts the ﬂexibility of the agonist and allosteric binding
sites to permit the development of nematode-speciﬁc compounds.
If this is not the case, then iGluR from parasitic nematodes may
have considerable potential as potential drug targets.3.1. Glutamate-gated chloride channels
The glutamate-gated chloride channels (GluCls) form a branch of
the ligand-gated ion channel family that is conﬁned to invertebrates
(Cleland, 1996). They aremost closely related tomammalian glycine
receptors and, more distantly, to the GABA-gated chloride channels
found throughout the animalkingdom(Vassilatis et al., 1997b;Dent,
2006). These channels are inhibitory under normal ionic conditions,
with Cl ions ﬂowing into the cell, hyperpolarizing it. They are the
targets of the ML group of anthelmintics, the biggest selling class
of drugs in veterinary medicine, which includes ivermectin and
moxidectin. These drugs are extremely potent anthelmintics,
insecticides and acaricides (Campbell et al., 1983), and bind nema-
tode GluCl with extremely high afﬁnity (Rohrer et al., 1994; Gill
and Lacey, 1998;Dent et al., 2000; Cheesemanet al., 2001). Recently,
Hibbs and Gouaux (2011) published the structure of a C. elegans
GluCl complexed with ivermectin (Fig. 1), showing the drug bound
in the pore region of the channel, between adjacent subunits. This
conﬁrmed earlier results, obtained from site-directed mutagenesis,
which had suggested that ivermectin binds to this site, which is
analogous to the anesthetic-binding site found on mammalian
Fig. 1. Structure of ivermectin bound to a glutamate-gated chloride channel. The
GluCl shown is formed of GLC-1 subunits (Cully et al., 1994). Two views are shown.
(A) The view is from the side of the receptor, looking parallel with the membrane.
(B) Looking down on the binding site from the outside of the cell, with the
extracellular part of the GluCl removed. The binding site is between the M3 helix of
the (+) subunit and M1 of the () subunit.

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long been known that although ivermectin can directly activate
some GluCl, it does not do so via binding to the normal agonist
binding site; activation by ivermectin is very slow but essentially
irreversible (Cully et al., 1994; Vassilatis et al., 1997a; Horoszok
et al., 2001; Forrester et al., 2003; Yates and Wolstenholme, 2004;
McCavera et al., 2009). The MLs also potentiate the activation of
the channels by the normal ligand, glutamate (Cully et al., 1994;
Forrester et al., 2002, 2004), and this may be the important effect
of the drug in vivo. The high-resolution structure of the GluCl pro-
vides a clear explanation for these physiological and pharmacologi-
cal ﬁndings; the hydrophobic MLs have to dissolve in the plasma
membrane of the cell expressing the GluCl and then bind to the pore
region of the receptor. It is not clear whether they can bind to the
closed state of the GluCl or must wait until it switches to the open
state, whether this is a spontaneous opening or caused by agonist
binding, but once bound the drug holds the channel in the open
state, preventing the a-helixes that form the pore region (Unwin,
2005) from rotating back to close the ion channel. The very slow
off-rate of ligand-binding results in a long-lasting, almost perma-
nent, channel-opening and hyperpolarization of the cell – rendering
it no longer excitable.The effects on the worms of this irreversible activation of inhib-
itory receptors will depend on where the channels are expressed.
Studies on C. elegans and parasitic species showed that the GluCl
were expressed on pharyngeal muscle and motor neurons, among
other cells (Dent et al., 1997, 2000; Laughton et al., 1997a; Portillo
et al., 2003; Glendinning et al., 2011), and effects on both locomo-
tion and feeding were observed on parasites, especially GI para-
sites, though some differences between species were also
observed (Kass et al., 1980; Geary et al., 1993; Sheriff et al., 2002,
2005; Holden-Dye and Walker, 2006; Tompkins et al., 2010). How-
ever, this does not explain all of the drug’s effects, for example, the
long-lasting sterilization of Onchocerca volvulus adults that is ob-
served in vivo (Awadzi et al., 1985). The in vitro concentrations of
the drugs that are required to directly inhibit nematode movement
or other processes in vitro are frequently much higher than those
that kill parasites in vivo; for example, the ML are effective heart-
worm preventatives at nanomolar concentrations in vivo, yet
in vitro micromolar concentrations are required to inhibit locomo-
tion (Evans et al., 2011). Recently, a novel explanation for the effect
of MLs on Brugia malayimicroﬁlariae has been proposed, inhibition
of protein secretion due to activation of GluCl expressed on the
muscle controlling the excretory/secretory pore (Moreno et al.,
2010). Such a mechanism could render the parasites more suscep-
tible to attack by components of the innate immune system
(Zahner et al., 1997), and at least partially explain the large gap be-
tween the in vivo and in vitro drug concentrations needed for
anthelmintic action. The GluCl subunit detected in the ES muscle,
AVR-14, is conserved in all nematodes studied so far (Laughton
et al., 1997b; Jagannathan et al., 1999; Njue et al., 2004; Yates
and Wolstenholme, 2004; Tandon et al., 2006; Williamson et al.,
2007; El-Abdellati et al., 2011), so this ﬁnding may have wider
implications for way the drug works in other parasites. AVR-14 is
also expressed on motor neurons (Dent et al., 2000; Portillo
et al., 2003; Glendinning et al., 2011) and is therefore involved in
locomotion, which might be why surrogate assays for resistance
which involve movement, such as the LMIA, are effective in some
species.
The GluCl are also expressed on sensory neurons, in amphids
and elsewhere (Rolfe et al., 2001; Portillo et al., 2003; Glendinning
et al., 2011), and it is also possible that the ML might affect sensory
processes, though this has been little studied. It is intriguing that
amphid derangement has been linked to ML-resistance in both
Haemonchus contortus and C. elegans (Freeman et al., 2003);
whether this reﬂects a direct drug effect on sensory processes or
perhaps its route on entry into the worm is not known.
3.2. Other ligand-gated chloride channels
The GluCl are famous as the target for the ML anthelmintics, but
nematodes possess a large number of ligand-gated chloride chan-
nels, with a greater variety of endogenous ligands than mammals.
It has long been known that nematodes have inhibitory GABA-
gated chloride channels at the neuromuscular junction (Holdendye
et al., 1989; Richmond and Jorgensen, 1999). These channels are
required because of the worm’s sinusoidal movement, with mus-
cles on either side of the body alternately contracting and relaxing
– the GABA receptors mediate the relaxation, so drug-induced acti-
vation of them induces a ﬂaccid paralysis. This is the mode of ac-
tion of piperazine (Martin et al., 1991), a GABA agonist that was
introduced as an anthelmintic in the 1950s. In addition, it has been
recently demonstrated that nematodes possess acetylcholine-, 5-
HT-, dopamine- and tyramine-gated chloride channels (Rangana-
than et al., 2000; Putrenko et al., 2005; Pirri et al., 2009; Ringstad
et al., 2009), none of which are present in mammals. The original
identiﬁcation of many of these channels was carried out on
C. elegans, but many of the genes are conserved in parasitic species
6 A.J. Wolstenholme / International Journal for Parasitology: Drugs and Drug Resistance 1 (2011) 2–13and one, the dopamine-gated chloride-channel gene Hco-ggr-3, has
been suggested to be associated with ML resistance in H. contortus
(Rao et al., 2009, 2010). Agonists and antagonists at these receptors
might be worth exploring for potential anthelmintic activity.
3.3. Nicotinic acetylcholine receptors
The nicotinic acetylcholine receptors (nAChR) are the targets of
a wide range of anthelmintic compounds (Martin, 1997). In most
cases, this is because they affect the nAChR at the nematode neu-
romuscular junction, causing, in the case of agonists, a rapid spastic
paralysis that presumably leads to the worms being expelled.
However, nematodes possess a wide diversity of nAChR, not only
at the neuromuscular junction but also in the nerve ring and in
the pharynx (Jones and Sattelle, 2004). The nAChR have a diverse
and fascinating pharmacology and it is this that has allowed the
development of so many drugs that target them. It might be as-
sumed that resistance to one such drug would lead to cross-resis-
tance to the others, but the recent experience with monepantel and
derquantel has shown that this is not the case (Kaminsky et al.,
2008a; Little et al., 2011).
3.3.1. Neuromuscular nAChR
The nAChR found at the neuromuscular junction (nmj) have
been the most intensively studied in nematodes, especially in C.
elegans and Ascaris suum, largely due to their genetic and physio-
logical accessibility, respectively. Studies on both worms have re-
vealed that there are multiple nAChR at the nematode nmj,
though the details vary between species. In C. elegans, there are
two clearly deﬁned receptors, one very sensitive to levamisole,
an important anthelmintic, and one not; the latter is sensitive to
nicotine (Richmond and Jorgensen, 1999). Genetic and in vitro
reconstitution studies have shown that the C. elegans levamisole-
sensitive receptor is made up of ﬁve subunits, LEV-1, LEV-8,Fig. 2. The inferred subunit composition of some nematode neuromuscular junction nAC
are activated by monepental and related drugs. (A) A levamisole-sensitive, but nicotine-i
elegans LEV-1, LEV_8, UNC-29, UNC-38 and UNC-63 subunits (Boulin et al., 2008). (B) A le
from H. contortus (Boulin et al., 2011). (C) A levamisole- and oxantel-sensitive, but pyrant
A. suum (Williamson et al., 2009). (D) A nicotine-sensitive, but levamisole-insensitive r
2000). (E) Omission of Hco-ACR-8 from the receptor shown in panel B results in a nAChR
et al., 2011). (F). Changing the ratio of the Asu-UNC-29 and -UNC-38 subunits results in
levamisole and which is oxantel insensitive (Williamson et al., 2009).UNC-29, UNC-38 and UNC-63 (Fig. 3) (Boulin et al., 2008), whereas
the levamisole-insensitive receptor is an ACR-16 homomer (Ray-
mond et al., 2000; Touroutine et al., 2005). However, this is not
the same in parasitic species. In H. contortus, there is no detectable
lev-8 gene and lev-1 does not seem to encode a functional nAChR
subunit; in this species the unc-29 gene has undergone multiple
duplications to create four very similar genes, Hco-unc-29.1–Hco-
unc-29.4. The H. contortus levamisole-sensitive receptor can be
reconstituted in Xenopus oocytes by expressing the ACR-8, UNC-
29, UNC-38 and UNC-63 subunits (Fig. 3) (Boulin et al., 2011).
Removing the ACR-8 subunit from the H. contortus receptor pro-
duces a version which gives a smaller response to levamisole and
acetylcholine, but is more sensitive to pyrantel, which is frequently
thought to act at the same site at levamisole (Martin et al., 1991;
Martin and Robertson, 2007). There are suggestions that increased
expression of receptors lacking ACR-8 might be associated with
levamisole resistance (Fauvin et al., 2010); if that is the case one
might speculate that the reduced efﬁcacy of acetylcholine at these
receptors could result in fairly rapid reversion of resistance if the
drug pressure is removed and the worms might also be predicted
to show an increased sensitivity to pyrantel.
The nAChR found at the A. suum nmj have been extensively
studied. These receptors are amenable to electrophysiological
studies because of the large size of the worm and the extrasynaptic
distribution of the receptors. These studies have identiﬁed three
physiological and pharmacological subtypes of nAChR in A. suum
– the so-called ‘N’ (for nicotine), ‘L’ (for levamisole) and ‘B’ (for
bephenium) sub-types (Martin et al., 2004a,b; Qian et al., 2006).
The names reﬂect those compounds that show selective activity
at those receptors. Despite the superﬁcial similarity to the C. ele-
gans receptors implied by these data, the results of in vitro recon-
stitution experiments were quite different; in this case, receptors
with properties similar to those of the ‘N’ and ‘L’ subtypes could
be produced by expression of just two subunits, Asu-UNC-29 andhR. Different forms of the receptor are found elsewhere in the nervous system, and
nsensitive nAChR was reconstituted in the Xenopus oocyte by co-expression of the C.
vamisole-sensitive nAChR reconstituted by co-expression of the indicated subunits
el-insensitive, nAChR reconstituted by co-expression of the indicated subunits from
eceptor is formed by expression of the C. elegans ACR-16 subunit (Raymond et al.,
with reduced sensitivity to levamisole, but increased sensitivity to pyrantel (Boulin
a receptor with increased sensitivity to nicotine and pyrantel, reduced sensitivity to
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two sub-types was the ratio of the two subunits in the pentameric
receptor (Fig. 2). Interestingly, a change in the ratio of the two sub-
units also produced changes in the sensitivity of the resulting
receptors to both pyrantel and oxantel, conﬁrming a previous re-
port that oxantel acted at the ‘N’ sub-type of the A. suum nAChR
rather than the ‘L’ sub-type, at which pyrantel was more active
(Martin et al., 2004b). Of course, such in vitro studies do not neces-
sarily reﬂect the in vivo composition of the receptors but they pro-
vide important information about which subunit combinations
may or may not be viable, and what their properties might be.
One exciting implication of the studies on both the A. suum and
H. contortus receptors is that resistance to levamisole might in-
crease susceptibility to pyrantel, and vice versa, so that it would
be difﬁcult for worms to become resistant to both drugs, despite
the fact that they apparently have the same target.
The nmj nAChR are also the targets of two newer drugs, triben-
dimidine and derquantel (Robertson et al., 2002; Hu et al., 2009;
Ruiz-Lancheros et al., 2011). Tribendimidine has been reported to
act as an agonist at the C. elegans levamisole-sensitive nAChR,
and also has important activities against ﬂukes, and derquantel
has been shown to antagonize nicotinic responses in both C. ele-
gans and A. suum. More detailed analysis suggests that derquantel
is most active against the ‘B’ sub-type of the A. suum nAChR. The
appearance of these drugs, and of the amino-acetonitrile deriva-
tives demonstrates that nAChR remain important molecules to
consider in anthelmintic drug discovery.
3.3.2. Other nAChR
Given the large number of nAChR subunit genes encoded by at
least some nematodes, it is not surprising that these receptors are
expressed in a large number of locations throughout the nervous
system and, at least in the case of C. elegans, in the pharynx (Treinin
and Chalﬁe, 1995; Jones and Sattelle, 2004; McKay et al., 2004;
Jospin et al., 2009). The pharmacology of some of these receptors
is signiﬁcantly different to those found at the nmj and this has
been exploited in the development of a novel anthelmintic
class, the amino-acetonitrile derivatives (AADs) (Kaminsky et al.,
2008a), one of which, AAD1566 or monepantel, has been commer-
cialized (Kaminsky et al., 2008b). These compounds act on
neuronal nAChR, and experiments using mutant strains of
C. elegans indicated that the target receptor included the ACR-23
and DES-2 subunits (Kaminsky et al., 2008a). These subunits form,
in C. elegans, a subfamily of nAChR which seem to be unique to
nematodes; other members of the family are DEG-3, ACR-5, ACR-
7, ACR-17, ACR-18 and ACR-20. There is evidence to suggest that
their normal ligand is in fact choline rather than acetylcholine
(Yassin et al., 2001; Rufener et al., 2010a). In H. contortus resistance
to monepantel was largely associated with mutations in the
Hco-mptl-1 gene, a member of the deg-3 sub-family most similar
to acr-20 (Rufener et al., 2009). Members of this family are widely
found across parasitic species and at least one member is present
in the genome of all parasites sequenced to date; however it has
been reported that the efﬁcacy of monepantel correlates with the
presence of an acr-23 or mptl-1(acr-20) ortholog (Rufener et al.,
2010b). These genes are absent from Pristionchus paciﬁcus,
Strongyloides ratti, B. malayi, Trichinella spiralis or A. suum. The nor-
mal functions of MPTL-1 and ACR-20 are not known; in C. elegans
knockdown of acr-23 expression by RNA interference is embryonic
lethal (Sonnichsen et al., 2005). Treatment of nematodes with
monepantel causes paralysis, presumably due either to activation
of neurons controlling movement or because the choline receptor
is also expressed on muscle cells; C. elegans DES-2 is expressed
on head muscles (Yassin et al., 2001).
In vitro, monepantel has been shown to act as a positive alloste-
ric modulator, enhancing the response to choline of a reconstitutednAChR containing the H. contortus DEG-3 and DES-2 subunits (Ruf-
ener et al., 2010a). However, the addition of MPTL-1 to this recep-
tor had no effect on either its response to choline or to monepantel,
whichmay mean that this subunit combination does not reﬂect the
native monepantel target. The inactive enantiomer of monepantel,
AAD-2224, was an antagonist at the Hco-DEG-3/Hco-DES-2
receptor.
The example of monepantel illustrates the potential of this un-
ique sub-family of nematode nAChR as potential drug targets. The
fact that this drug is effective against parasites resistant to other
nicotinic drugs again shows that we cannot assume that the emer-
gence of resistance to one nicotinic drug, such as levamisole, im-
plies that this will inevitably cause cross-resistance to the others.
For the worms, their neurochemical complexity may, in this case,
be a two-edged sword; as they adapt to cope with the pressure ap-
plied by one drug, they may make themselves more vulnerable to
other compounds. The trick for those interested in control may be
to keep up with those changes and to respond quickly and effec-
tively to alterations in the parasites resistance/susceptibility spec-
trum as they arise.4. Other ion channels
4.1. Potassium channels
In excitable cells such as neurons and muscle, the membrane
potential and generation of action potentials is largely controlled
by ion channels that open and close in response to changes in
the membrane potential and other signals. Three families of volt-
age-operated cation channels are present in vertebrates, gating so-
dium, potassium and calcium, respectively. No voltage-operated
sodium channels have been detected in nematodes and it is be-
lieved that their ‘action potentials’ are calcium-dependent (Mellem
et al., 2008; Gao and Zhen, 2011). A considerable number of human
pharmaceuticals act as modulators of voltage-operated channels,
as do many toxins, so it would not be surprising if compounds
could be developed that would speciﬁcally activate or block nem-
atode channels. Such compounds would be predicted to seriously
affect neuronal signaling, causing the death of the parasite.
To date, only one anthelmintic, emodepside, has been shown to
require a voltage-gated ion channel for its activity (Guest et al.,
2007; Welz et al., 2011). Emodepside inhibits locomotion, feeding,
egg-laying and slows development of C. elegans and parasitic
worms (Harder et al., 2003; Willson et al., 2003; Bull et al., 2007;
Welz et al., 2011), and these multiple effects may be due to
activation of more than one target. Following a screen to identify
C. elegans mutants resistant to emodepside, it was found that
worms with loss-of-function mutations in slo-1, a gene that en-
codes a voltage- and calcium-activated potassium, or BK, channel
(Atkinson et al., 1991), are resistant to emodepside inhibition of
locomotion and pharyngeal pumping whereas gain-of-function
mutants in the same gene phenocopy the action of the drug (Guest
et al., 2007). Evidence that this mode of action was conserved in
parasites was recently provided by the successful expression of
SLO-1 from Ancylostoma caninum and Cooperia oncophora in a slo-
1 mutant of C. elegans; this restored susceptibility to the drug
(Welz et al., 2011), whereas expression of the human form of the
protein did not (Crisford et al., 2011). SLO-1 channels are highly
conserved, regulating neurosecretion, hormone release, muscle
contraction, and neuronal excitability (Salkoff et al., 2006), which
is consistent with the multiple effects of the drug seen in vivo. A
very recent paper (Buxton et al., 2011) has conﬁrmed that SLO-1
is conserved in A. suum, along with LAT-1 (see Section 5) and that
both are expressed in muscle ﬂaps. Application of emodepside to
this preparation produced a slow increase in voltage-activated K+
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crease was enhanced by pharmacological stimulation of the pro-
tein kinase C (PKC) and nitric oxide (NO) signaling pathways.
One interpretation of these ﬁndings is that, although the anthel-
mintic effects of emodepside are manifested through SLO-1 activa-
tion, the actual target of the drug is upstream of the channel,
potentially activating it via PKC and/or NO.
To date, none of the other nematocidal drugs in current use
have effects on voltage-operated ion channels, though praziquan-
tel, the mainstay of current schistosomiasis chemotherapy, has
been shown to activate schistosome calcium channels in vitro
(Kohn et al., 2001; Greenberg, 2005). Kwok et al. (2006) demon-
strated that C. elegans genetic screens could be used to identify no-
vel small molecule inhibitors of voltage-operated calcium
channels, but these do not seem to have been developed for any
anthelmintic activity.4.2. Other ion channels
All animals, including nematodes, possess several other families
of ion channels that are expressed in the nervous system. To date,
none of these have been exploited in anthelmintic drug develop-
ment, though the intracellular ryanodine receptors are the targets
of the phthalic acid diamide and anthranilic diamide classes of
insecticides (Sattelle et al., 2008); these receptors are conserved
in nematodes, where they are encoded by the unc-68 gene (Maryon
et al., 1996). Parasitic nematodes possess multiple TRP channels
(Wolstenholme et al., 2011), which in C. elegans and other phyla
are involved in multiple sensory processes (Chalﬁe, 2009; Garrity
et al., 2010) and might be interesting potential targets. Another po-
tential ion channel target is the DEG/ENaC (named after the C. ele-
gans degenerins and the mammalian epithelial amiloride-sensitive
Na+ channel) family of sodium channels. In the worm, the genes
encoding these channels were originally identiﬁed because domi-
nant mutant alleles caused inappropriate cell death (Driscoll,
1992), later found to be due to their constitutive activation (Hong
and Driscoll, 1994). This property would suggest that speciﬁc ago-
nists of these receptors might make useful anthelmintics, though
they may not as fast-acting as those that induce paralysis.5. G protein-coupled receptors
The G protein-coupled receptors (GPCRs) make up the largest
family of proteins in the nervous system, with about 900 genes
encoding these receptors in the C. elegans genome (Bargmann,
1998). However, a large proportion of these are olfactory receptors
which are not well conserved in parasitic species and may not be
considered to be good drug targets. The ligands for many others
have not yet been identiﬁed; many of these may be peptide recep-
tors (see Section 6) or ‘hormone’-like receptors not expressed so-
lely in the nervous system and therefore not strictly within the
scope of this review. However, this still leaves many GPCRs that
are expressed within the nervous system that might be viable tar-
gets for anthelmintic drugs. Table 1 shows that, if this is the case,
they have not been exploited so far.
There is one possible exception to this. Emodepside, in addition
to its action at SLO-1 potassium channels, binds to Hc-110R, a
GPCR from H. contortus that also acts as a receptor for latrotoxin,
a toxin from the black widow spider (Saeger et al., 2001). This
receptor, also called latrophilin or depsiphilin (Kruger et al.,
2009), is encoded by the lat-1 gene in C. elegans. Activation of
Hc-110R or LAT-1 inhibits pharyngeal pumping in both the para-
site and C. elegans (Willson et al., 2004). However, LAT-1 does
not mediate the effects of emodepside on C. elegans locomotion
(Bull et al., 2007; Guest et al., 2007). Latrophilins are conservedin animal nervous systems and are found in the pre-synaptic mem-
brane, where they induce transmitter release (Silva et al., 2009) via
an interaction with UNC-13 dependent vesicle priming (Willson
et al., 2004). In C. elegans at least, the evidence seems clear that
SLO-1 is a more important emodepside target than LAT-1, but it
is possible that this is not the case for all the parasites against
which the drug is active.
Many neurotransmitters act via GPCRs (Fig. 3), which can be
present on pre-, post- and extra-synaptic membranes and whose
function may be to modulate fast neurotransmission mediated by
ligand-gated ion channels. A well studied group is the biogenic
amines, which includes 5-hydroxytryptamine (5-HT, or serotonin),
dopamine, tyramine and octopamine. All of these molecules act at
GPCRs (Komuniecki et al., 2004), though, as stated earlier, nema-
todes also possess chloride channels gated by 5-HT, dopamine
and tyramine. At least some of these receptors have also been iden-
tiﬁed in parasitic species (Huang et al., 1999, 2002; Smith et al.,
2003, 2007) and many have distinct pharmacological characteris-
tics that suggest that nematode-speciﬁc agonists and antagonists
could be developed as useful anthelmintics (White et al., 2007).
In C. elegans, dopamine and 5-HT have well-established roles in
modulating behavior, including locomotion, feeding and egg-lay-
ing (Chase and Koelle, 2007). In H. contortus, 5-HT was detected
in amphid and pharyngeal neurons, and in male-speciﬁc neurons,
whereas dopamine was only found in motor neuron commissures;
application of either caused inhibition of movement, in the case of
dopamine this was conﬁned to the central part of the worm (Rao
et al., 1987). Exogenous 5-HT also stimulates feeding in A. suum
and Nippostrongylus brasiliensis (Brownlee et al., 1997; Trim et al.,
2001; Huang et al., 2010). By contrast, it had no effect on the con-
tractile activity of Diroﬁlaria immitis (Bowen and Vitayavirasak,
2008).
Other classical neurotransmitters, including acetylcholine and
GABA, also act at G-protein coupled receptors and regulate nema-
tode locomotion (Dittman and Kaplan, 2008). ACh acts at musca-
rinic receptors, encoded in nematodes by the gar genes (Hwang
et al., 1999; Lee et al., 1999, 2000). These are present in parasitic
species, and have atypical muscarinic pharmacology (Segerberg
and Stretton, 1993; Kimber et al., 2009), which again suggest that
helminth-speciﬁc molecules could be developed.6. Peptide signaling systems
Nematodes encode a multitude of peptide transmitters and hor-
mones, including FLPs (FMRFamide-like peptides), NLPs (neuro-
peptide-like peptides) and insulin-like peptides (Li and Kim,
2010; Marks and Maule, 2010) and more continue to be discovered
(Jarecki et al., 2011); these peptides play multiple modulating roles
in the nervous system (McVeigh et al., 2006; Husson et al., 2007;
Walker et al., 2009). Many of the peptides in nematodes, such as
the FLPs, are not found in mammals and so peptidergic signaling
by these molecules can be considered a promising target for new
drug discovery (Martin and Robertson, 2010). Despite the example
of emodepside (Harder and von Samson-Himmelstjerna, 2002),
peptides themselves are generally considered unpromising mole-
cules from which to develop anthelmintic drugs, and so attention
has focused on the use of non-peptide small molecules (Geary,
2010). Many peptides act at GPCRs; though a huge number of neu-
ropeptides has been identiﬁed by biochemical and genetic means,
the identiﬁcation of the cognate receptors for these peptides has
lagged somewhat behind. Interestingly, when surface plasmon res-
onance studies were carried out using a recombinant 54 kDa ami-
noterminal fragment of HC110-R, the latrophilin-like molecule
identiﬁed as a possible emodepside receptor (Saeger et al., 2001),
AF1, AF10, and PF2, three FMRFamide-like peptides, were found
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might act on this receptor to modulate pharyngeal pumping. Some
peptides, for example, PF4, may directly gate ion channels (Purcell
et al., 2002) and, if rapid and easily observable effects are desired,
might be more proﬁtable leads to follow. Signaling downstream of
the peptide receptors will affect many other components of the
nervous system, and effects on the conductance of potassium and
calcium channels have been observed (Verma et al., 2007, 2009),
showing the cross-talk that exists between peptide and other sig-
naling pathways.7. Other aspects of neurotransmission
7.1. Acetylcholinesterase
Acetylcholinesterase (AChE) is responsible for breaking down
acetylcholine once it has bound to, and activated, its receptors.
Inhibition of this enzyme therefore causes a spastic paralysis
through enhancing Ach activity and this has been exploited not
only in the development of pesticides and anthelmintics, but also
nerve gases (Martin, 1997). Organophosphates, such as dichlorvos
and halaxon, and carbamates have been used to control plant and
animal parasitic nematodes (Selkirk et al., 2005) and act by cova-
lently modifying the active site of the enzyme. Perhaps not surpris-
ingly, these compounds have safety problems and they are now
little used for treating parasitic nematode infections. However, itFig. 3. Current and potential anthelmintic targets in the nematode nervous system. A
cholinergic, the other glutamatergic. No such arrangement may be present in the nema
positions shown here. The targets of four anthelmintic drug families are indicated:
imidazothiazoles, tetrahydropyrimidine, amino-acetonitrile derivatives, tribendimidine
same form of the nAChR (see Fig. 2); (3) emodepside acts at SLO-1 Ca2+-activated K+ c
inhibitors of acetylcholinesterase. Many other voltage-operated ion channels, transpo
anthelmintic development.may still be possible to produce selective inhibitors of nematode
AChEs. A very interesting variant form of AChE is that secreted
by many parasitic nematodes, especially those that colonize muco-
sal surfaces within the gastro-intestinal tract (Ogilvie et al., 1973;
Selkirk et al., 2005). N. brasiliensis secretes three such enzymes
(Hussein et al., 1999, 2002a,b), Dictyocaulus viviparous secretes at
least two (Lazari et al., 2003), Trichostrongylus colubriformis and
Necator americanus at least one (Grifﬁths and Pritchard, 1994;
Pritchard et al., 1994).
7.2. Other potential targets
Neurotransmission involves a large number of proteins and cel-
lular process, many of which are unique to excitable cells. Practi-
cally all of these are conserved in nematodes, and could,
potentially, be exploited as anthelmintic targets. Many of these pro-
teins and processes have been targeted for therapeutic purposes in
mammals, which demonstrate at least the theoretical possibility
that helminth speciﬁc compounds could be developed. Potential
targets, in addition to those already discussed, could include the
transporters that carry transmitters across plasma and vesicle
membranes, selective serotonin reuptake inhibitors are an example
of a drug class that acts here (Briley and Moret, 1993), or the
enzymes involved in the biosynthesis, processing and degradation
of transmitters, especially of neuropeptides (Londershausen,
1996). There are also many downstream signaling proteins and
chaperones that are essential for accurate neurotransmission andhighly diagrammatic representation of a cell receiving two synaptic inputs, one
tode nervous system, but the molecules shown do exist, even if not in the relative
(1) The macrocyclic lactones act as glutamate-gated chloride channels; (2) the
and spiro-indoles all act at nicotinic acetylcholine receptors, though not all to the
hannels and at presynaptic latrophilin receptors; (4) organophosphates are potent
rters and G-protein coupled receptors are present and are potential targets for
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or deleterious to C. elegans, but whose potential as antiparasitic tar-
gets remains unexplored.
8. Concluding remarks
The nematode nervous system has long been a proﬁtable source
of anthelmintic drugs, and this looks set to continue. The advanta-
ges of interfering with neurotransmission are obvious if your goal
is to kill a multi-cellular organism, and this has been exploited for
the control of worms, insects, lice, mollusks and, unfortunately,
mammals. Not only is the effect rapid, it is often very easy to ob-
serve and many of the molecules involved are amenable to high-
throughput screening strategies (Woods and Knauer, 2010; Woods
et al., 2011). Fig. 3 shows some of the proteins and processes tar-
geted by our existing anti-nematode drugs, put into the context
of a theoretical and highly-stylized synapse. The ﬁgure also serves
to highlight some of the other potential targets present at the same
structure. These other targets may be worth considering, as the
limitations of our current anthelmintics, especially for human
medicine (Geary et al., 2010), the problems of resistance in the vet-
erinary arena (Kaplan, 2004) and the almost complete lack of good
methods for controlling plant parasitic nematodes (Holden-Dye
andWalker, 2011; Molinari, 2011), make the investment in contin-
ued anthelmintic discovery essential. Regardless of whether any
individual component of the nematode synapse turns out to be
useful in drug development, it seems certain that the nervous sys-
tem as a whole will continue to be studied and exploited for many
years to come.
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